OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:03 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

NCT06279195 · Endeavor Health · PHASE2 · withdrawn · last registry update 2025-08-28 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Could not obtain approval for the planned study with available funding”–Registry record, Endeavor Health

Also happening at the time. Not shown to be a cause.

No drug target was found for this trial's interventions, so there is no same-target timeline.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision